Panbela Therapeutics Stock Price, News & Analysis
Company Description
Panbela Therapeutics (OTC Link: PBLA) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $242.7K.
PBLA stock has declined 100.0% over the past year. Shares last traded at $0.0002.
This page provides a comprehensive overview of PBLA stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Panbela Therapeutics (PBLA) stock last traded at $0.0002. Over the past 12 months, the stock has lost 100.0%. At a market capitalization of $242.7K, PBLA is classified as a micro-cap stock with approximately 4.9M shares outstanding.
Latest News
Panbela Therapeutics has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, conferences, clinical trial. View all PBLA news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Panbela Therapeutics (PBLA) currently stands at 3 shares, representing 0.0% of the float. Over the past 12 months, short interest has decreased by 99%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Panbela Therapeutics (PBLA) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.
PBLA Company Profile & Sector Positioning
Panbela Therapeutics (PBLA) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing PBLA often look at related companies in the same sector, including Vincerx Pharma Inc (VINC), Trevena Inc (TRVN), Altamira Therapeutics Ltd (CYTOF), Respirerx Pharma (RSPI), and Scorpius Holdings (SCPX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate PBLA's relative position within its industry.